All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Ruben A. Mesa, UT Health San Antonio, San Antonio, US. We asked, FREEDOM trial: How can we manage adverse events (AEs) associated with fedratinib?
FREEDOM trial: How can we manage AEs associated with fedratinib?
In this video, Mesa discusses results from the FREEDOM trial (NCT03755518), a phase 3b, multicenter study evaluating the safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib. Lastly, he mentions the management of fedratinib side effects, including gastrointestinal complications, and monitoring of thiamine levels.
Review of novel agents for myeloproliferative neoplasms
In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal transducers and activators of transcription (JAK/STAT)...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate-2 or high-risk primary or secondary...
Subscribe to get the best content related to MPN delivered to your inbox